







European Social Fund Plus 2021/2027 The state of the sta

PPO 2023 S.P. 22/23

Support for higher education within the regional university

With Decree No. 17895/GRFVG of April 19, 2023, the Friuli Venezia Giulia Region published the Notice regarding the submission of operations for Specific Program No. 22/23, which aims to support higher education within the regional university system.

Line A – PhD Programmes

Specific Programme 22/23, through the funding of doctoral scholarships, contributes to the achievement of the objectives of the Sustainable Smart Specialisation Strategy (S4). It supports the development or strengthening of integration with the regional production system and/or research organisations, through coordination and collaboration mechanisms with regional enterprises or research bodies, or by leveraging the potential for technology transfer of processes, products, applications, or, more broadly, research outcomes.

- Notice **2023**
- 39th cycle
- Unique Project Code (CUP) J93C23001490008
- Project 2023/1578/9

Doctoral Programme in Personalized Medicine and Innovative Therapies

"Precision medicine and personalized therapies for Burlo"

The project contents will align with the scientific objectives related to the current research lines of the IRCCS Burlo Garofolo Maternal and Child Health Institute, which are closely connected to the research activities promoted by the PhD program. These include biomedical, experimental, and clinical research activities, structured along three main lines: fetal-neonatal health from prevention to clinical practice; medical and surgical sciences of childhood and adolescence; and advanced diagnostic innovation.

In particular, the focus will be on the development and implementation of innovative diagnostic technologies for rare and hereditary diseases, microbiome studies, dysbiosis and inflammation, development of diagnostic markers and nanomedicine, pharmacokinetics, pharmacodynamics and pharmacogenetics, innovative therapies, development of patient-specific preclinical models, drug repurposing, and biorepository/biobanking.

The research activities, centered on precision medicine and personalized therapies, will be carried out at the Institute or at collaborating facilities under specific agreements or partnerships.